Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.
Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna / Lallas, A; Moscarella, E; Kittler, H; Longo, C; Thomas, L; Zalaudek, I; Kyrgidis, A; Manoli, S M; di Meo, N; Papageorgiou, C; Apalla, Z; Argenziano, G. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 185:3(2021), pp. 675-677. [10.1111/bjd.20407]
Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Longo, C;Zalaudek, I;di Meo, N;
2021-01-01
Abstract
Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.| File | Dimensione | Formato | |
|---|---|---|---|
|
bjd.20407.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Digital Rights Management non definito
Dimensione
1.12 MB
Formato
Adobe PDF
|
1.12 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
bjd.20407-Post_print.pdf
accesso aperto
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Creative commons
Dimensione
871.1 kB
Formato
Adobe PDF
|
871.1 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
